4AP to Delay Carpal Tunnel Release (CTR)
The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression) Standard of care EDX testing within 6 months of study enrollment Cognitive ability to report sensory and motor deficit during examination. Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period. Adults subject aged 18-90 Ability to give written informed consent. Capable of safely undergoing electrodiagnostic testing (EDX). Availability for all study visits.  Exclusion Criteria:  Inability to complete twice daily dosing during 6 week treatment period. History of multiple sclerosis, stroke or any other diagnosed neurological disorder History of hypersensitivity to AMPYRA® or 4-aminopyridine Current use of aminopyridine medications, including other compounded 4-AP Suspected renal impairment based on the Choyke questionnaire. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult